AOCI at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax.
The official record: BioMarin Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioMarin Pharmaceuticals's aoci.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioMarin Pharmaceuticals's AOCI?
- BioMarin Pharmaceuticals (BMRN) reported AOCI of -$4.24M in Q1 2026.
- How has BioMarin Pharmaceuticals's AOCI changed year-over-year?
- BioMarin Pharmaceuticals's AOCI decreased by 122.1% year-over-year, from $19.15M to -$4.24M.
- What is the long-term trend for BioMarin Pharmaceuticals's AOCI?
- Over 5 years (2020 to 2025), BioMarin Pharmaceuticals's AOCI has grown at a -3.5% compound annual growth rate (CAGR), from -$16.14M to -$13.47M.
- What does AOCI mean?
- The cumulative total of unrealized gains and losses that bypass the income statement.
- How do you interpret AOCI?
- Fluctuations often signal changes in foreign exchange rates or market valuations of investment portfolios rather than core operational performance.
- How does AOCI compare across companies?
- Standard line item for all public companies; volatility depends on the company's international exposure and hedging strategy.